According to official health reports, a 52-year old man in China contracted the H5N1 strain of avian influenza from his son late last year. The two were diagnosed within the same week of each other but while the 24-year-old died his father survived after receiving early antiviral treatment and post-vaccination plasma from a participant in an H5N1 vaccine trial.
A study of this confirmed case of human-human transmission, one of only a dozen worldwide, was published on-line in The Lancet on April 8. According to a team of Chinese and US researchers, the younger man's only plausible exposure to H5N1 virus was a poultry market visit six days before onset, while the father had close exposure to his ill son. 91 contacts were identified that were exposed to one or both cases. Of these individuals, 78 (86%) received chemoprophylaxis with Roche's Tamiflu (oseltamivir), the main antiviral stockpiled around the world against a possible bird flu pandemic, and two had mild illness.
Both ill contacts tested negative for H5N1 and all 91 close contacts tested negative for H5N1 antibodies. H5N1 viruses isolated from the two cases were genetically identical except for one non-synonymous nucleotide substitution, the researchers noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze